Skip to main content
. 2014 Apr 18;5(9):2778–2791. doi: 10.18632/oncotarget.1916

Figure 8. (A) Concurrent downregulation of IDO and BRCA2 sensitizes A549 to cisplatin in an additive fashion.

Figure 8

Bars represent the means of 3 independent measurements of cells (with or without downregulation of IDO) after BRCA2 siRNA transfection + cisplatin treatment (n=3 for each measurement) ± SEM. **Different from treatment with either siRNA in combination with cisplatin (p≤0.05). (B) Data from panel A rearranged to show the effect of combined IDO and BRCA2 downregulation on A549 sensitivity to cisplatin. *Different from values in lanes 6 and 7.